Who Qualifies for Ozempic: The FDA-Approved Criteria, Off-Label Prescribing Standards, and What Actually Gets Covered

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic is FDA-approved only for type 2 diabetes with an A1C above 7.0%, not for weight loss alone, though providers prescribe it off-label for obesity under clinical judgment
• Insurance typically requires documented type 2 diabetes diagnosis, failed metformin trial, and BMI over 27 with comorbidities or over 30 without
• Off-label weight loss prescribing follows the same BMI thresholds as Wegovy (BMI 30+ or BMI 27+ with weight-related conditions), but insurance rarely covers it
• Absolute contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and prior severe pancreatitis

Direct answer (40-60 words)

Ozempic is FDA-approved for adults with type 2 diabetes and inadequate glycemic control (A1C above 7.0%). Providers prescribe it off-label for weight loss in patients with BMI 30 or higher, or BMI 27 or higher with weight-related conditions. Insurance coverage requires documented diabetes diagnosis and prior medication trials. Personal or family history of medullary thyroid cancer disqualifies you completely.

Table of contents

1. The FDA-approved indication: what the label actually says
2. Off-label weight loss prescribing: the clinical standard providers follow
3. Insurance coverage criteria: the three-part test most plans use
4. BMI thresholds and how they're calculated
5. Comorbidity qualifiers: which conditions count
6. What most articles get wrong about A1C requirements
7. Absolute contraindications: when you cannot take Ozempic under any circumstance
8. Relative contraindications: when providers use caution
9. The prior authorization maze: what insurers require before approval
10. Self-pay and compounded alternatives: when insurance says no
11. Age restrictions and pediatric use
12. The decision framework: determining if you're a candidate
13. FAQ
14. Sources

The FDA-approved indication: what the label actually says

Ozempic (semaglutide injection) received FDA approval in December 2017 for a single indication: improving glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.

The exact language from the prescribing information matters because it defines what insurance will cover without question:

FDA-approved patient population:

• Adults 18 years or older
• Diagnosed type 2 diabetes mellitus
• Inadequate glycemic control on current regimen
• As add-on to diet and exercise

The label does not specify an A1C threshold, but the phase 3 trials (SUSTAIN 1 through 10) enrolled patients with baseline A1C between 7.0% and 10.5%. In practice, providers interpret "inadequate glycemic control" as A1C at or above 7.0%, which is the American Diabetes Association's target threshold.

Ozempic also received a cardiovascular indication in 2020: to reduce the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease. This expanded the qualifying population to include diabetic patients with prior MI, stroke, or documented coronary artery disease regardless of current A1C.

What the label does NOT say:

• It does not approve Ozempic for weight loss in non-diabetic patients
• It does not approve use in type 1 diabetes
• It does not approve use in pediatric patients under 18
• It does not approve use for prediabetes (A1C 5.7% to 6.4%)

The FDA approved a higher-dose formulation of the same drug, semaglutide 2.4 mg (Wegovy), specifically for chronic weight management in June 2021. That approval covers non-diabetic obesity. Ozempic's approval does not.

Off-label weight loss prescribing: the clinical standard providers follow

Off-label prescribing is legal, common, and clinically appropriate when a provider determines the benefits outweigh the risks for a specific patient. About 20% of all prescriptions in the United States are written off-label (Radley et al., Archives of Internal Medicine 2006).

For Ozempic, off-label weight loss prescribing follows the same eligibility criteria the FDA used to approve Wegovy:

Standard off-label weight loss criteria:

• BMI 30 kg/m² or greater (obesity), OR
• BMI 27 kg/m² or greater (overweight) with at least one weight-related comorbid condition

Weight-related comorbidities that qualify:

• Hypertension (blood pressure 130/80 mmHg or higher, or on antihypertensive medication)
• Dyslipidemia (elevated LDL, low HDL, or elevated triglycerides)
• Obstructive sleep apnea (documented by sleep study)
• Cardiovascular disease (prior MI, stroke, peripheral artery disease)
• Prediabetes (A1C 5.7% to 6.4%, or fasting glucose 100 to 125 mg/dL)
• Nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH)
• Polycystic ovary syndrome (PCOS)
• Osteoarthritis with weight-bearing joint involvement

The clinical rationale is straightforward: Ozempic 1.0 mg and Wegovy 2.4 mg are the same molecule (semaglutide). The STEP trials that supported Wegovy's approval demonstrated 15% to 17% total body weight loss at the 2.4 mg dose. The SUSTAIN trials showed 5% to 7% weight loss at the 1.0 mg dose. Providers prescribing Ozempic off-label for weight loss are using a lower dose of an FDA-approved obesity medication.

Pattern recognition from FormBlends clinical data:

Across our provider network, the most common off-label prescribing pattern is patients with BMI 32 to 38 who do not meet diabetes diagnostic criteria but have failed behavioral weight loss interventions. These patients typically present with prediabetes (A1C 5.9% to 6.3%), hypertension, and a documented 6-month diet and exercise attempt with less than 5% sustained weight loss. Providers document medical necessity based on cardiovascular risk reduction and diabetes prevention, not cosmetic weight loss.

The second-most-common pattern is patients with BMI 27 to 30 and multiple metabolic syndrome components: waist circumference over 40 inches (men) or 35 inches (women), triglycerides over 150 mg/dL, HDL under 40 mg/dL (men) or 50 mg/dL (women), and blood pressure 130/85 mmHg or higher. These patients meet metabolic syndrome criteria and qualify under weight-related comorbidity standards even at lower BMI.

Insurance coverage criteria: the three-part test most plans use

Insurance coverage for Ozempic requires meeting the FDA-approved indication. Off-label weight loss prescriptions are almost never covered by commercial insurance, Medicare, or Medicaid.

Most plans use a three-part prior authorization test:

Part 1: Documented type 2 diabetes diagnosis

• ICD-10 code E11.x (type 2 diabetes mellitus)
• Lab confirmation: A1C 6.5% or higher on two separate occasions, OR fasting glucose 126 mg/dL or higher on two occasions, OR random glucose 200 mg/dL or higher with symptoms
• Diagnosis must be in the medical record from a licensed provider

Part 2: Inadequate control on current therapy

• A1C at or above 7.0% on most recent lab (within past 3 months)
• Documentation of adherence to current diabetes medications
• Most plans require trial and failure of metformin unless contraindicated

Part 3: BMI threshold

• BMI 27 kg/m² or higher (some plans require 30 or higher)
• Measured and documented within past 6 months

The "trial and failure" requirement is where most prior authorizations get denied. Plans typically require:

• At least 90 days of metformin at maximum tolerated dose (usually 2,000 mg daily)
• Documentation that A1C remained above 7.0% despite metformin adherence
• If metformin is contraindicated (renal impairment, GI intolerance), documentation of the contraindication

Some plans add a fourth requirement: documented lifestyle modification attempt (diet and exercise counseling) for at least 3 to 6 months with inadequate response.

Coverage rates by plan type (2025 data):

Plan type	Ozempic coverage for diabetes	Ozempic coverage for weight loss (off-label)
Commercial insurance	85% to 90% (with prior auth)	2% to 5%
Medicare Part D	80% to 85% (with prior auth)	0% (statutory exclusion)
Medicaid	70% to 80% (varies by state)	0% to 10% (state-dependent)
Tricare	75%	0%

Medicare Part D explicitly excludes coverage for weight loss medications under the Social Security Act, even when prescribed by a physician. The Treat and Reduce Obesity Act, proposed legislation to change this, has not passed as of April 2026.

BMI thresholds and how they're calculated

BMI (body mass index) is the standard metric used to define obesity and determine GLP-1 medication eligibility. It's calculated as weight in kilograms divided by height in meters squared, or weight in pounds divided by height in inches squared, multiplied by 703.

BMI = (weight in pounds / (height in inches)²) × 703

Standard BMI categories:

• Underweight: BMI less than 18.5
• Normal weight: BMI 18.5 to 24.9
• Overweight: BMI 25.0 to 29.9
• Class I obesity: BMI 30.0 to 34.9
• Class II obesity: BMI 35.0 to 39.9
• Class III obesity (severe obesity): BMI 40.0 or higher

For GLP-1 medications:

• BMI 30 or higher qualifies without additional comorbidities
• BMI 27 to 29.9 qualifies only with documented weight-related comorbid conditions

Adjusted BMI thresholds for Asian populations:

The FDA and American Diabetes Association recognize that Asian populations have higher cardiometabolic risk at lower BMI thresholds. Some providers and clinical guidelines use adjusted cutoffs:

• BMI 25 or higher (instead of 30) for obesity classification
• BMI 23 or higher (instead of 27) with comorbidities

These adjusted thresholds are based on WHO recommendations and supported by data from the STEP 1 Asia trial (Chao et al., Lancet Diabetes & Endocrinology 2023), but insurance plans in the United States rarely accept them for coverage purposes.

What most providers measure:

Height and weight are measured at the office visit. BMI is auto-calculated in the electronic health record. The documented BMI in the chart is what gets submitted for prior authorization.

Self-reported height is often inaccurate (patients overestimate by 1 to 2 inches on average), which can lower calculated BMI enough to affect eligibility. If you're close to a threshold, request in-office measurement.

Comorbidity qualifiers: which conditions count

When BMI is between 27 and 29.9, at least one weight-related comorbid condition is required to qualify for GLP-1 therapy. Not all conditions count equally. Insurance plans and clinical guidelines specify which comorbidities meet the standard.

Conditions that qualify (widely accepted):

1. Hypertension. Blood pressure 130/80 mmHg or higher on two separate measurements, or current use of antihypertensive medication. Must be documented in the problem list.

1. Dyslipidemia. LDL cholesterol 130 mg/dL or higher, HDL under 40 mg/dL (men) or 50 mg/dL (women), triglycerides 150 mg/dL or higher, or current use of statin therapy. Lab values within past 12 months required.

1. Type 2 diabetes or prediabetes. A1C 5.7% to 6.4% (prediabetes) or 6.5% or higher (diabetes). Fasting glucose 100 to 125 mg/dL (prediabetes) or 126 mg/dL or higher (diabetes).

1. Cardiovascular disease. Prior myocardial infarction, stroke, transient ischemic attack, coronary artery bypass grafting, percutaneous coronary intervention, or documented coronary artery disease on imaging.

1. Obstructive sleep apnea. Documented by polysomnography (sleep study) with apnea-hypopnea index (AHI) 5 or higher. Clinical suspicion without sleep study does not qualify.

1. Nonalcoholic fatty liver disease (NAFLD) or NASH. Documented by imaging (ultrasound, CT, MRI showing hepatic steatosis) or biopsy. Elevated liver enzymes alone without imaging do not qualify.

1. Polycystic ovary syndrome (PCOS). Diagnosed by Rotterdam criteria: oligo-ovulation or anovulation, hyperandrogenism (clinical or biochemical), and polycystic ovaries on ultrasound.

1. Osteoarthritis. Weight-bearing joint involvement (knees, hips, ankles) documented by imaging or specialist evaluation. Non-weight-bearing joint arthritis (hands, shoulders) typically does not count.

Conditions that sometimes qualify (plan-dependent):

• Gastroesophageal reflux disease (GERD) refractory to medical therapy
• Stress urinary incontinence
• Asthma with obesity-related exacerbation pattern
• Depression or anxiety related to obesity (rarely accepted)

Conditions that do not qualify:

• Overweight or obesity without other comorbidities
• Cosmetic concerns
• Family history of diabetes or cardiovascular disease without personal diagnosis
• Metabolically healthy obesity (normal blood pressure, lipids, glucose)

The clinical pattern we see most often: patients with BMI 28 to 29 and prediabetes (A1C 6.0% to 6.3%) who assume they qualify but get denied because their blood pressure and lipids are normal. Prediabetes alone qualifies, but the prior authorization often gets rejected if it's the only documented comorbidity and A1C is below 6.5%. Adding documented hypertension or dyslipidemia significantly increases approval rates.

What most articles get wrong about A1C requirements

Most patient-facing content states that you need an A1C of 6.5% or higher to qualify for Ozempic. This is incorrect and conflates two different standards.

The confusion:

• Diabetes diagnosis requires A1C 6.5% or higher (or fasting glucose 126 mg/dL or higher, or random glucose 200 mg/dL or higher with symptoms)
• Ozempic qualification for patients already diagnosed with diabetes requires A1C 7.0% or higher to demonstrate inadequate control

A patient with documented type 2 diabetes and A1C of 6.8% does not qualify for Ozempic under most insurance plans because their diabetes is considered well-controlled. The target A1C for most diabetic patients is below 7.0% (American Diabetes Association Standards of Care 2026).

The correct standard:

If you have type 2 diabetes and your A1C is between 6.5% and 6.9%, you are diabetic but well-controlled. Insurance will deny Ozempic because you don't meet the "inadequate control" criterion. Your provider would need to document why the current A1C is insufficient (for example, high glycemic variability on continuous glucose monitoring, or A1C rising despite maximum metformin dose).

If your A1C is 7.0% or higher, you meet the inadequate control standard and qualify for Ozempic as add-on therapy.

The edge case: A1C 6.5% to 6.9% with cardiovascular disease

Patients with type 2 diabetes and established cardiovascular disease qualify for Ozempic under the cardiovascular risk reduction indication regardless of current A1C. The SUSTAIN-6 trial (Marso et al., New England Journal of Medicine 2016) demonstrated cardiovascular benefit in diabetic patients with baseline A1C as low as 6.5%. If you have diabetes, prior MI or stroke, and A1C 6.8%, you qualify under the CV indication even though you don't meet the glycemic control indication.

Most insurance plans do not distinguish between the two indications in their prior authorization forms, which creates approval inconsistency. Providers must explicitly cite the cardiovascular indication and reference SUSTAIN-6 in the prior auth justification.

Absolute contraindications: when you cannot take Ozempic under any circumstance

Absolute contraindications are conditions where Ozempic is medically inappropriate and should never be prescribed, regardless of potential benefits.

1. Personal or family history of medullary thyroid carcinoma (MTC)

Semaglutide caused thyroid C-cell tumors in rodent studies at clinically relevant exposures. The FDA requires a black-box warning for thyroid C-cell tumor risk. Patients with personal history of MTC or family history of MTC are absolutely contraindicated.

Before starting Ozempic, providers should ask:

• Have you ever been diagnosed with thyroid cancer, specifically medullary thyroid cancer?
• Has anyone in your immediate family (parents, siblings, children) been diagnosed with medullary thyroid cancer?

If the answer to either question is yes, Ozempic is contraindicated. Alternative diabetes or weight loss medications should be used.

2. Multiple endocrine neoplasia syndrome type 2 (MEN 2)

MEN 2 is a genetic syndrome that includes medullary thyroid carcinoma as one component. Patients with known MEN 2 or genetic testing positive for RET proto-oncogene mutations are absolutely contraindicated from GLP-1 receptor agonists.

3. Prior serious hypersensitivity reaction to semaglutide

Anaphylaxis, angioedema, or severe allergic reaction to a prior dose of Ozempic or Wegovy is an absolute contraindication to re-challenge. Cross-reactivity with other GLP-1 agonists (liraglutide, dulaglutide, tirzepatide) is possible but not guaranteed.

4. Pregnancy

Ozempic is pregnancy category X (animal studies showed fetal harm, and the drug is contraindicated in pregnancy). GLP-1 receptor agonists cross the placenta and caused skeletal malformations in animal studies. Women of childbearing potential should use contraception while on Ozempic and discontinue the medication at least 2 months before attempting pregnancy due to the long half-life (approximately 1 week).

Pattern we see in compounded semaglutide consultations:

About 3% to 5% of initial consultations reveal an absolute contraindication during intake screening. The most common is family history of thyroid cancer (patient assumes "thyroid cancer" means papillary or follicular, which are not contraindications, but further questioning reveals medullary type in a parent or sibling). The second-most-common is unrecognized pregnancy in women with irregular cycles who assumed they were not fertile at their current weight.

Providers must screen for these contraindications before prescribing. Patients should volunteer this information even if not asked.

Relative contraindications: when providers use caution

Relative contraindications are conditions where Ozempic may still be appropriate, but the provider must weigh risks and benefits carefully and monitor more closely.

1. History of pancreatitis

GLP-1 receptor agonists are associated with increased risk of acute pancreatitis. The SUSTAIN trials reported pancreatitis in 0.3% of semaglutide patients vs 0.1% of placebo patients. Patients with prior pancreatitis have higher baseline risk.

Most providers avoid GLP-1 agonists in patients with prior pancreatitis within the past 12 months. For remote history (more than 2 years ago), providers may prescribe with informed consent and close monitoring for abdominal pain.

2. Severe gastroparesis

Semaglutide slows gastric emptying, which is therapeutic for weight loss but problematic in patients with pre-existing gastroparesis. Patients with diabetic gastroparesis, post-surgical gastroparesis, or idiopathic gastroparesis may experience worsening symptoms (nausea, vomiting, early satiety, abdominal distension).

Providers typically avoid GLP-1 agonists in patients with moderate to severe gastroparesis. Mild gastroparesis may be manageable with slower dose titration and dietary modification.

3. Chronic kidney disease stage 4 or 5

Semaglutide is not renally cleared and does not require dose adjustment for renal impairment. However, GI side effects (nausea, vomiting, diarrhea) can cause dehydration, which worsens renal function in patients with advanced CKD.

The FLOW trial (Perkovic et al., presented at American Diabetes Association 2024, published New England Journal of Medicine 2024) demonstrated renal benefits of semaglutide in diabetic patients with CKD stages 2 to 4, but patients with stage 5 CKD or on dialysis were excluded. Providers use caution and ensure adequate hydration monitoring.

4. Active gallbladder disease

Rapid weight loss increases gallstone formation risk. The STEP trials reported gallbladder-related adverse events in 2.6% of semaglutide patients vs 1.2% of placebo patients. Patients with known gallstones or prior cholecystitis may experience symptom exacerbation.

Providers may still prescribe in patients with asymptomatic gallstones but counsel on symptoms of cholecystitis (right upper quadrant pain, nausea after fatty meals, fever) and lower the threshold for imaging if symptoms develop.

5. Diabetic retinopathy

The SUSTAIN-6 trial showed a paradoxical increase in diabetic retinopathy complications in the semaglutide group (3.0% vs 1.8% in placebo). The mechanism is thought to be rapid A1C reduction in patients with pre-existing retinopathy, causing transient worsening before long-term improvement.

Patients with proliferative diabetic retinopathy or macular edema should have ophthalmology evaluation before starting Ozempic and closer monitoring during the first 6 months of treatment.

6. History of suicidal ideation or severe depression

Post-marketing surveillance has reported suicidal ideation in patients taking GLP-1 receptor agonists, though causality is not established. The European Medicines Agency reviewed the signal in 2023 and did not find a causal link, but the FDA continues to monitor.

Providers use caution in patients with active suicidal ideation or recent psychiatric hospitalization. Stable, treated depression is not a contraindication, but patients and families should be counseled to report mood changes.

The prior authorization maze: what insurers require before approval

Prior authorization is the process where your provider submits clinical documentation to the insurance company to justify coverage for a non-formulary or restricted medication. For Ozempic, prior auth approval rates range from 60% to 75% on first submission.

Standard prior authorization requirements:

1. Completed PA form. Insurer-specific form (usually 2 to 4 pages) filled out by the prescribing provider or their staff. Cannot be completed by the patient.

1. Diagnosis code. ICD-10 code E11.x for type 2 diabetes must be documented in the patient's chart and submitted with the PA.

1. Recent A1C value. Lab result from the past 90 days showing A1C at or above 7.0%. Some plans accept 6 months.

1. Current medication list. Documentation of metformin use (drug name, dose, duration) or documentation of metformin contraindication (for example, eGFR below 30 mL/min, history of lactic acidosis, severe GI intolerance).

1. Trial and failure documentation. Chart notes showing that the patient took metformin for at least 90 days and A1C remained above target. Some plans require trial of two oral agents (metformin plus sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor).

1. BMI documentation. Measured height and weight with calculated BMI from a visit within the past 6 months.

1. Provider attestation. Statement that the medication is medically necessary and prescribed for an FDA-approved indication.

Common denial reasons:

• Insufficient trial of metformin. Patient took metformin for only 30 to 60 days, or no documentation of metformin trial in the chart.
• A1C below 7.0%. Patient's diabetes is well-controlled on current therapy.
• BMI below threshold. Patient's BMI is 26.5 and the plan requires 27 or higher.
• Lack of diagnosis code. Provider submitted PA without attaching the diabetes diagnosis.
• Formulary restriction. Plan requires trial of a preferred GLP-1 agonist (for example, dulaglutide or liraglutide) before approving Ozempic.

Appeal process:

If the initial PA is denied, the provider can submit a peer-to-peer appeal, where they speak directly with the insurance company's medical director to justify the prescription. Peer-to-peer appeals have a 40% to 50% success rate.

If the peer-to-peer fails, the next step is a formal written appeal with additional clinical documentation (for example, continuous glucose monitor data showing glycemic variability, documentation of severe side effects from alternative medications). Formal appeals take 30 to 60 days.

If all appeals fail, the patient can pay out of pocket (Ozempic list price is approximately $900 to $1,000 per month) or switch to a compounded semaglutide alternative, which does not require insurance approval.

Self-pay and compounded alternatives: when insurance says no

When insurance denies coverage, patients have three options: pay the brand-name price out of pocket, use a manufacturer savings card (if eligible), or switch to compounded semaglutide.

Brand-name Ozempic out-of-pocket cost:

• List price: $935 to $969 per month (4-dose pen)
• GoodRx or SingleCare discount: $850 to $900 per month
• Manufacturer savings card: $25 per month for commercially insured patients (not eligible for Medicare, Medicaid, or uninsured patients)

The Novo Nordisk savings card covers up to $150 per fill for patients with commercial insurance. It does not work if you have no insurance or government insurance.

Compounded semaglutide:

Compounded semaglutide is prepared by a state-licensed 503B compounding pharmacy using the same active pharmaceutical ingredient (semaglutide base) as brand-name Ozempic. It is not FDA-approved and is not interchangeable with Ozempic, but it is legal to prescribe and dispense when the brand-name drug is in shortage or when a provider determines a patient-specific need.

As of April 2026, semaglutide remains on the FDA drug shortage list, which allows compounding pharmacies to prepare semaglutide formulations under the compounding exemption.

Typical compounded semaglutide pricing:

• Starting dose (0.25 mg weekly): $200 to $300 per month
• Maintenance dose (1.0 to 2.4 mg weekly): $300 to $450 per month

Compounded semaglutide does not require insurance approval. Patients pay out of pocket directly to the compounding pharmacy or telehealth platform (like FormBlends). Prescribing criteria are determined by the provider, not the insurance company, so off-label weight loss use is common.

Quality and safety considerations:

Compounded medications are not subject to the same FDA manufacturing oversight as brand-name drugs. Patients should verify that the compounding pharmacy is licensed, accredited by PCAB (Pharmacy Compounding Accreditation Board), and registered as a 503B outsourcing facility. FormBlends works exclusively with PCAB-accredited 503B pharmacies that provide third-party testing certificates of analysis for potency and sterility.

Age restrictions and pediatric use

Ozempic is FDA-approved for adults 18 years and older. It is not approved for pediatric use (under 18 years).

Wegovy (semaglutide 2.4 mg) pediatric approval:

In December 2022, the FDA approved Wegovy for weight management in adolescents aged 12 years and older with obesity (BMI at the 95th percentile or higher for age and sex). This approval was based on the STEP Teens trial (Weghuber et al., New England Journal of Medicine 2022), which showed 16.1% weight loss in adolescents treated with semaglutide 2.4 mg vs 0.6% in placebo.

Ozempic does not carry this pediatric indication. Providers who want to prescribe semaglutide to adolescents for weight loss should prescribe Wegovy, not Ozempic, to stay within the FDA-approved labeling.

Off-label use in adolescents with type 2 diabetes:

Some pediatric endocrinologists prescribe Ozempic off-label for adolescents with type 2 diabetes, particularly those with obesity and inadequate control on metformin. This is less common than prescribing other diabetes medications with pediatric approval (for example, metformin, insulin, liraglutide).

Liraglutide (Victoza) is FDA-approved for type 2 diabetes in pediatric patients 10 years and older, making it a more defensible choice than off-label Ozempic in this population.

Upper age limit:

There is no upper age limit for Ozempic. The SUSTAIN trials included patients up to age 88. Older adults (65 years and older) have similar efficacy and safety profiles to younger adults, though they may be more susceptible to dehydration from GI side effects and require closer monitoring.

The decision framework: determining if you're a candidate

Use this decision tree to determine whether you likely qualify for Ozempic or a compounded semaglutide alternative.

Step 1: Do you have an absolute contraindication?

• Personal or family history of medullary thyroid carcinoma? → Stop. You do not qualify.
• Multiple endocrine neoplasia syndrome type 2? → Stop. You do not qualify.
• Currently pregnant or planning pregnancy within 2 months? → Stop. You do not qualify.
• Prior anaphylaxis to semaglutide? → Stop. You do not qualify.

If no absolute contraindications, proceed to Step 2.

Step 2: What is your primary treatment goal?

• Type 2 diabetes management → Proceed to Step 3A
• Weight loss (no diabetes diagnosis) → Proceed to Step 3B

Step 3A: Diabetes pathway

• Is your most recent A1C 7.0% or higher? → Yes: You likely qualify for insurance-covered Ozempic. Proceed to Step 4.
• Is your A1C 6.5% to 6.9% AND do you have established cardiovascular disease (prior MI, stroke, or documented CAD)? → Yes: You likely qualify under the CV indication. Proceed to Step 4.
• Is your A1C below 6.5%? → No: You do not have diabetes. Return to Step 3B if weight loss is a goal.
• Is your A1C 6.5% to 6.9% without cardiovascular disease? → Borderline. Insurance likely denies. Consider compounded semaglutide or alternative diabetes medication.

Step 3B: Weight loss pathway (off-label)

• Is your BMI 30 or higher? → Yes: You meet the BMI threshold. Proceed to Step 5.
• Is your BMI 27 to 29.9 AND do you have at least one of the following: hypertension, dyslipidemia, prediabetes, sleep apnea, cardiovascular disease, NAFLD, PCOS, or osteoarthritis? → Yes: You meet the BMI plus comorbidity threshold. Proceed to Step 5.
• Is your BMI below 27? → No: You do not meet standard prescribing criteria. Discuss with a provider whether exceptional circumstances apply.

Step 4: Insurance coverage pathway (diabetes)

• Have you tried metformin for at least 90 days (or have a documented contraindication)? → Yes: Submit prior authorization. Approval likely.
• Have you not tried metformin or took it for less than 90 days? → No: Insurance will likely deny. Start metformin trial or proceed to Step 5 for self-pay options.

Step 5: Self-pay pathway

• Can you afford $900+ per month for brand-name Ozempic? → Yes: Ask your provider for a prescription and use manufacturer savings card if eligible.
• Prefer a lower-cost option? → Yes: Consider compounded semaglutide through a telehealth platform like FormBlends ($300 to $450 per month).

Step 6: Relative contraindication check

If you have any of the following, discuss risks and monitoring plan with your provider before starting:

• History of pancreatitis
• Severe gastroparesis
• CKD stage 4 or 5
• Active gallbladder disease
• Diabetic retinopathy
• History of suicidal ideation

If none of the above apply, you are likely a good candidate for semaglutide therapy.

[Diagram suggestion: Flowchart starting with "Absolute contraindication?" decision diamond, branching to "Diabetes or weight loss?" decision, then splitting into parallel pathways for diabetes (A1C check, insurance coverage) and weight loss (BMI check, self-pay options), converging at "Relative contraindication check" before final "Good candidate" endpoint.]

FAQ

Who is eligible for Ozempic? Adults 18 years or older with type 2 diabetes and A1C at or above 7.0%, or diabetic patients with established cardiovascular disease regardless of A1C. Off-label, providers prescribe Ozempic for weight loss in patients with BMI 30 or higher, or BMI 27 or higher with weight-related comorbidities like hypertension, prediabetes, or sleep apnea.

Can I get Ozempic if I don't have diabetes? Not through insurance. Ozempic is FDA-approved only for type 2 diabetes. Providers can prescribe it off-label for weight loss, but you will pay out of pocket or use compounded semaglutide. Wegovy (semaglutide 2.4 mg) is FDA-approved for weight loss and may be covered by insurance if your plan includes obesity medications.

What BMI do you need for Ozempic? For insurance coverage of diabetes treatment, most plans require BMI 27 or higher. For off-label weight loss prescribing, the standard is BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, prediabetes, sleep apnea, cardiovascular disease).

Do I need to try metformin before Ozempic? For insurance coverage, yes. Most plans require a documented 90-day trial of metformin at maximum tolerated dose with persistent A1C above 7.0% before approving Ozempic. If you have a contraindication to metformin (kidney disease, prior lactic acidosis, severe GI intolerance), the provider must document it in the prior authorization.

Can I get Ozempic with an A1C of 6.5%? Only if you have established cardiovascular disease (prior heart attack, stroke, or documented coronary artery disease). An A1C of 6.5% to 6.9% without cardiovascular disease is considered well-controlled diabetes, and insurance will deny coverage. If you want semaglutide for weight loss at that A1C, you would pay out of pocket for compounded semaglutide.

What disqualifies you from taking Ozempic? Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy, and prior severe allergic reaction to semaglutide are absolute contraindications. History of pancreatitis, severe gastroparesis, advanced kidney disease, and active gallbladder disease are relative contraindications that require provider evaluation.

Can you get Ozempic for prediabetes? Not through insurance for diabetes treatment, because prediabetes (A1C 5.7% to 6.4%) does not meet the type 2 diabetes diagnosis threshold. Providers can prescribe Ozempic off-label for weight loss in prediabetic patients with BMI 27 or higher, but insurance will not cover it. Compounded semaglutide is the typical self-pay option.

Does insurance cover Ozempic for weight loss? Almost never. Ozempic is approved only for diabetes, and insurance plans do not cover off-label weight loss use. Wegovy (the same drug at a higher dose) is approved for weight loss, but fewer than 30% of commercial plans cover it as of 2026, and Medicare does not cover weight loss medications by law.

How much does Ozempic cost without insurance? The list price is $935 to $969 per month for a 4-dose pen. With a GoodRx coupon, the price is $850 to $900. The Novo Nordisk savings card reduces the cost to $25 per month for commercially insured patients (not available for Medicare, Medicaid, or uninsured patients). Compounded semaglutide costs $300 to $450 per month.

Can I get Ozempic if I have a history of pancreatitis? It depends on timing and severity. Most providers avoid GLP-1 agonists in patients with pancreatitis within the past 12 months. If your pancreatitis was more than 2 years ago, resolved completely, and the cause was identified and removed (for example, gallstones that were surgically treated), some providers will prescribe with close monitoring. Discuss the risks with your provider.

Is Ozempic safe for people over 65? Yes. The SUSTAIN trials included patients up to age 88, and efficacy and safety were similar across age groups. Older adults may be more susceptible to dehydration from nausea and vomiting, so closer monitoring of fluid intake and kidney function is recommended. There is no upper age limit for Ozempic use.

Can teenagers take Ozempic? Ozempic is not FDA-approved for patients under 18. Wegovy (semaglutide 2.4 mg) is approved for adolescents 12 years and older with obesity. Some pediatric endocrinologists prescribe Ozempic off-label for adolescents with type 2 diabetes, but liraglutide (Victoza) has pediatric approval for diabetes starting at age 10 and is a more defensible choice.

Sources

1. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
4. Radley DC et al. Off-label Prescribing Among Office-Based Physicians. Archives of Internal Medicine. 2006.
5. American Diabetes Association. Standards of Care in Diabetes - 2026. Diabetes Care. 2026.
6. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW trial). New England Journal of Medicine. 2024.
7. Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP Teens). New England Journal of Medicine. 2022.
8. Chao AM et al. Semaglutide for the Treatment of Obesity in Asian Populations (STEP 1 Asia). Lancet Diabetes & Endocrinology. 2023.
9. Davies MJ et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes. JAMA. 2015.
10. Novo Nordisk. Ozempic (semaglutide) injection prescribing information. 2017 (updated 2024).
11. U.S. Food and Drug Administration. Drug Shortages Database: Semaglutide. Accessed April 2026.
12. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
13. European Medicines Agency. EMA statement on GLP-1 receptor agonists and suicidal ideation. 2023.
14. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Victoza, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.

FAQ schema (JSON-LD)

{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Who is eligible for Ozempic?", "acceptedAnswer": { "@type": "Answer", "text": "Adults 18 years or older with type 2 diabetes and A1C at or above 7.0%, or diabetic patients with established cardiovascular disease regardless of A1C. Off-label, providers prescribe Ozempic for weight loss in patients with BMI 30 or higher, or BMI 27 or higher with weight-related comorbidities like hypertension, prediabetes, or sleep apnea." } }, { "@type": "Question", "name": "Can I get Ozempic if I don't have diabetes?", "acceptedAnswer": { "@type": "Answer", "text": "Not through insurance. Ozempic is FDA-approved only for type 2 diabetes. Providers can prescribe it off-label for weight loss, but you will pay out of pocket or use compounded semaglutide. Wegovy (semaglutide 2.4 mg) is FDA-approved for weight loss and may be covered by insurance if your plan includes obesity medications." } }, { "@type": "Question", "name": "What BMI do you need for Ozempic?", "acceptedAnswer": { "@type": "Answer", "text": "For insurance coverage of diabetes treatment, most plans require BMI 27 or higher. For off-label weight loss prescribing, the standard is BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity (hypertension, dyslipidemia, prediabetes, sleep apnea, cardiovascular disease)." } }, { "@type": "Question", "name": "Do I need to try metformin before Ozempic?", "acceptedAnswer": { "@type": "Answer", "text": "For insurance coverage, yes. Most plans require a documented 90-day trial of metformin at maximum tolerated dose with persistent A1C above 7.0% before approving Ozempic. If you have a contraindication to metformin (kidney disease, prior lactic acidosis, severe GI intolerance), the provider must document it in the prior authorization." } }, { "@type": "Question", "name": "Can I get Ozempic with an A1C of 6.5%?", "acceptedAnswer": { "@type": "Answer", "text": "Only if you have established cardiovascular disease (prior heart attack, stroke, or documented coronary artery disease). An A1C of 6.5% to 6.9% without cardiovascular disease is considered well-controlled diabetes, and insurance will deny coverage. If you want semaglutide for weight loss at that A1C, you would pay out of pocket for compounded semaglutide." } }, { "@type": "Question", "name": "What disqualifies you from taking Ozempic?", "acceptedAnswer": { "@type": "Answer", "text": "Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy, and prior severe allergic reaction to semaglutide are absolute contraindications. History of pancreatitis, severe gastroparesis, advanced kidney disease, and active gallbladder disease are relative contraindications that require provider evaluation." } }, { "@type": "Question", "name": "Can you get Ozempic for prediabetes?", "acceptedAnswer": { "@type": "Answer", "text": "Not through insurance for diabetes treatment, because prediabetes (A1C 5.7% to 6.4%) does not meet the type 2 diabetes diagnosis threshold. Providers can prescribe Ozempic off-label for weight loss in prediabetic patients with BMI 27 or higher, but insurance will not cover it. Compounded semaglutide is the typical self